Skip to main content
icon for Hantavirus vaccine in 2026?

Hantavirus vaccine in 2026?

icon for Hantavirus vaccine in 2026?

Hantavirus vaccine in 2026?

6% chance
Polymarket

$129,605 Vol.

6% chance
Polymarket

$129,605 Vol.

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine candidate has advanced to Phase 3 trials as of mid-2026, making regulatory approval by year-end highly improbable under standard FDA pathways. Recent outbreaks, including Andes virus cases on a cruise ship, have accelerated preclinical work on mRNA and structure-based candidates targeting the Gn-Gc spike, with mouse and hamster studies showing neutralizing antibody responses. However, these remain early-stage, with no human efficacy data and historical timelines indicating several years for full development even with accelerated review. Realistic shifts could occur only through unprecedented emergency funding or streamlined global trials, though current pipeline conditions strongly support trader consensus against availability this year.

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$129,605
End Date
Dec 31, 2026
Market Opened
May 4, 2026, 10:39 AM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine candidate has advanced to Phase 3 trials as of mid-2026, making regulatory approval by year-end highly improbable under standard FDA pathways. Recent outbreaks, including Andes virus cases on a cruise ship, have accelerated preclinical work on mRNA and structure-based candidates targeting the Gn-Gc spike, with mouse and hamster studies showing neutralizing antibody responses. However, these remain early-stage, with no human efficacy data and historical timelines indicating several years for full development even with accelerated review. Realistic shifts could occur only through unprecedented emergency funding or streamlined global trials, though current pipeline conditions strongly support trader consensus against availability this year.

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$129,605
End Date
Dec 31, 2026
Market Opened
May 4, 2026, 10:39 AM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.

Related

icon for Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

4%
icon for New pandemic in 2026?

New pandemic in 2026?

7%
icon for Ebola pandemic in 2026?

Ebola pandemic in 2026?

4%

Beware of external links.

Frequently Asked Questions

"Hantavirus vaccine in 2026?" is a prediction market on Polymarket where traders buy and sell "Yes" or "No" shares based on whether they believe this event will happen. The current crowd-sourced probability is 6% for "Yes." For example, if "Yes" is priced at 6¢, the market collectively assigns a 6% chance that this event will occur. These odds shift continuously as traders react to new developments and information. Shares in the correct outcome are redeemable for $1 each upon market resolution.

As of today, "Hantavirus vaccine in 2026?" has generated $129.6K in total trading volume since the market launched on May 4, 2026. This level of trading activity reflects strong engagement from the Polymarket community and helps ensure that the current odds are informed by a deep pool of market participants. You can track live price movements and trade on any outcome directly on this page.

To trade on "Hantavirus vaccine in 2026?," simply choose whether you believe the answer is "Yes" or "No." Each side has a current price that reflects the market's implied probability. Enter your amount and click "Trade." If you buy "Yes" shares and the outcome resolves as "Yes," each share pays out $1. If it resolves as "No," your "Yes" shares pay $0. You can also sell your shares at any time before resolution if you want to lock in a profit or cut a loss.

The current probability for "Hantavirus vaccine in 2026?" is 6% for "Yes." This means the Polymarket crowd currently believes there is a 6% chance that this event will occur. These odds update in real-time based on actual trades, providing a continuously updated signal of what the market expects to happen.

The resolution rules for "Hantavirus vaccine in 2026?" define exactly what needs to happen for each outcome to be declared a winner — including the official data sources used to determine the result. You can review the complete resolution criteria in the "Rules" section on this page above the comments. We recommend reading the rules carefully before trading, as they specify the precise conditions, edge cases, and sources that govern how this market is settled.